Literature DB >> 7438120

Continuous infusion vindesine in solid tumors.

G P Bodey, H Y Yap, B S Yap, M Valdivieso.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438120     DOI: 10.1016/s0305-7372(80)80006-5

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  7 in total

1.  Stabilization of vinca alkaloids encapsulated in poly(lactide-co-glycolide) microspheres.

Authors:  J Marinina; A Shenderova; S R Mallery; S P Schwendeman
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

2.  Pharmacokinetics of vindesine bolus and infusion.

Authors:  D V Jackson; V S Sethi; T R Long; H B Muss; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine.

Authors:  J A Young; S B Howell; M R Green
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 4.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

5.  Continuous intravenous infusion of vinca alkaloid using a subcutaneously implanted pump in a canine model.

Authors:  D V Jackson; M L Barringer; D L Rosenbaum; T R Long; J M Sterchi; W Meredith; V S Sethi; E J Modest; H B Wells; C L Spurr; M C Castle
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

6.  Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion.

Authors:  N S Tchekmedyian; M J Egorin; B E Cohen; R S Kaplan; E Poplin; J Aisner
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Antidote studies of vinorelbine-induced skin ulceration in the mouse.

Authors:  R T Dorr; K L Bool
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.